• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

    11/14/24 4:50:28 PM ET
    $VRNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VRNA alert in real time by email
    SC 13G/A 1 d912088dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Verona Pharma plc

    (Name of Issuer)

    Ordinary shares, nominal value £0.05 per share

    (Title of Class of Securities)

    925050106**

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐

    Rule 13d-1(b)

     

    ☒

    Rule 13d-1(c)

     

    ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **

    The CUSIP number is for the American Depositary Shares that trade on the NASDAQ Global Market, each representing eight ordinary shares. No CUSIP number has been assigned to the ordinary shares.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 925050106**

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Advisors LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     6,565,933 (1)

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     6,565,933 (1)

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,565,933 (1)

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     8.1%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IA

     

    (1)

    Represents (i) 6,315,933 American Depositary Shares (“ADSs”) representing 50,527,464 Ordinary Shares of the Issuer, and (ii) 250,000 ADS issuable upon exercise of options held by the Reporting Persons representing 2,000,000 Ordinary Shares of the Issuer. Each ADS represents eight Ordinary Shares.


    CUSIP No. 925050106**

     

     1   

     NAMES OF REPORTING PERSONS

     

     Joseph Edelman

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States of America

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     6,565,933 (1)

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     6,565,933 (1)

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,565,933 (1)

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     8.1%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     IN

     

    (1)

    Represents (i) 6,315,933 ADSs representing 50,527,464 Ordinary Shares of the Issuer, and (ii) 250,000 ADS issuable upon exercise of options held by the Reporting Persons representing 2,000,000 Ordinary Shares of the Issuer. Each ADS represents eight Ordinary Shares.


    CUSIP No. 925050106**

     

     1   

     NAMES OF REPORTING PERSONS

     

     Perceptive Life Sciences Master Fund, Ltd.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Cayman Islands

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH:

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     6,565,933 (1)

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     6,565,933 (1)

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     6,565,933 (1)

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     8.1%

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

     CO

     

    (1)

    Represents (i) 6,315,933 ADSs representing 50,527,464 Ordinary Shares of the Issuer, and (ii) 250,000 ADS issuable upon exercise of options held by the Reporting Persons representing 2,000,000 Ordinary Shares of the Issuer. Each ADS represents eight Ordinary Shares.


    Item 1(a).

    Name of Issuer:

    Verona Pharma plc (the “Issuer”)

     

    Item 1(b).

    Address of Issuer’s Principal Executive Offices:

    3 More London Riverside

    London SE1 2RE

    United Kingdom

     

    Item 2(a).

    Names of Persons Filing:

    The names of the persons filing this report (collectively, the “Reporting Persons”) are:

    Perceptive Advisors LLC (“Perceptive Advisors”)

    Joseph Edelman (“Mr. Edelman”)

    Perceptive Life Sciences Master Fund, Ltd. (the “Master Fund”)

     

    Item 2(b).

    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of the Reporting Persons is:

    51 Astor Place, 10th Floor

    New York, NY 10003

     

    Item 2(c).

    Citizenship:

    Perceptive Advisors is a Delaware limited liability company

    Mr. Edelman is a United States citizen

    The Master Fund is a Cayman Islands corporation

     

    Item 2(d).

    Title of Class of Securities:

    Ordinary shares, nominal value £0.05 per share (“Ordinary Shares”)

     

    Item 2(e).

    CUSIP Number:

    925050106

    The CUSIP number is for the American Depositary Shares (“ADSs”) that trade on the NASDAQ Global Market, each representing eight Ordinary Shares. No CUSIP number has been assigned to the Ordinary Shares.

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.


    Item 4.

    Ownership.

    The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. The ownership percentages are based on 649,881,246 outstanding Ordinary Shares, which if all held in ADS form, would be represented by 81,235,156 ADSs, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024.

    Neither Perceptive Advisors nor Mr. Edelman directly holds any Ordinary Shares. The Master Fund directly holds (i) 6,315,933 ADSs representing 50,527,464 Ordinary Shares, and (ii) 250,000 ADS issuable upon exercise of options held by the Master Fund representing 2,000,000 Ordinary Shares. Each ADS represents eight Ordinary Shares. Perceptive Advisors serves as the investment manager to the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: November 14, 2024

     

    PERCEPTIVE ADVISORS LLC
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title: Managing Member

    /s/ Joseph Edelman

    JOSEPH EDELMAN
    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.
    By:   Perceptive Advisors LLC
    By:  

    /s/ Joseph Edelman

      Name: Joseph Edelman
      Title: Managing Member
    Get the next $VRNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VRNA

    DatePrice TargetRatingAnalyst
    4/28/2025$100.00Buy
    TD Cowen
    4/21/2025$80.00Overweight
    Cantor Fitzgerald
    1/10/2025$68.00Buy
    ROTH MKM
    10/3/2024$50.00Overweight
    Wells Fargo
    5/22/2023$35.00 → $38.00Buy
    Jefferies
    9/19/2022$27.00Outperform
    Wedbush
    8/26/2022$31.00Overweight
    Piper Sandler
    11/12/2021$18.00 → $23.00Buy
    Canaccord Genuity
    More analyst ratings

    $VRNA
    SEC Filings

    See more
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      5/2/25 4:24:30 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      5/2/25 4:24:08 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Verona Pharma plc

      144 - Verona Pharma plc (0001657312) (Subject)

      4/29/25 4:21:40 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025

      Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease ("COPD"), two from nonclinical studies, and one from a real-world data analysis, will be presented at the American Thoracic Society Conference ("ATS") 2025. The posters are published on the ATS website an

      5/6/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar

      4/29/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

      LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States+1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Comp

      4/15/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

      Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

      10/8/24 5:00:00 AM ET
      $ENTO
      $OCS
      $ONCO
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports First Quarter 2021 Financial Results and Provides Corporate Update

      ENHANCE Phase 3 program enrollment continues on track to complete in 2H21 Board strengthened with NED appointment of Lisa Deschamps Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its financial results for the three months ended March 31, 2021, and provides a corporate update. "The first quarter of 2021 set a positive tone for what we expect to be another exciting year of substantial progress for Verona Pharma," said David Zaccardelli, Pharm. D., President and Chief E

      4/29/21 2:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ebsworth David R bought $88,800 worth of Ordinary Shares (20,000 units at $4.44), increasing direct ownership by 2% to 940,003 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/18/24 4:20:05 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ebsworth David R bought $188,881 worth of Ordinary Shares (39,360 units at $4.80), increasing direct ownership by 4% to 920,003 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/7/24 6:57:21 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ackermann Christina bought $198,386 worth of Ordinary Shares (41,880 units at $4.74) (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      11/7/24 6:56:12 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Financials

    Live finance-specific insights

    See more
    • Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2025, and provides a corporate update. "The remarkably strong US launch of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonar

      4/29/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update

      LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company") announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-800-715-9871 for callers in the United States+1-646-307-1963 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the Comp

      4/15/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

      OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2024, and provide

      2/27/25 6:00:00 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Rickard Kathleen A. sold $1,014,343 worth of Ordinary Shares (114,984 units at $8.82), decreasing direct ownership by 4% to 2,546,472 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/8/25 4:30:16 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Rickard Kathleen A. sold $440,350 worth of Ordinary Shares (49,200 units at $8.95) and converted options into 50,000 units of Ordinary Shares, increasing direct ownership by 0.03% to 2,661,456 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/5/25 4:32:18 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Hahn Mark W sold $5,311,479 worth of Ordinary Shares (587,008 units at $9.05) and converted options into 200,000 units of Ordinary Shares, decreasing direct ownership by 3% to 13,078,992 units (SEC Form 4)

      4 - Verona Pharma plc (0001657312) (Issuer)

      5/5/25 4:31:33 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • TD Cowen initiated coverage on Verona Pharma with a new price target

      TD Cowen initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $100.00

      4/28/25 8:38:21 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Verona Pharma with a new price target

      Cantor Fitzgerald initiated coverage of Verona Pharma with a rating of Overweight and set a new price target of $80.00

      4/21/25 8:39:43 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM initiated coverage on Verona Pharma with a new price target

      ROTH MKM initiated coverage of Verona Pharma with a rating of Buy and set a new price target of $68.00

      1/10/25 8:44:57 AM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      11/14/24 5:46:11 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verona Pharma plc

      SC 13G/A - Verona Pharma plc (0001657312) (Subject)

      11/14/24 4:50:28 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Verona Pharma plc

      SC 13G - Verona Pharma plc (0001657312) (Subject)

      11/14/24 4:31:56 PM ET
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care